End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
28.75 TWD | +2.86% | +2.68% | +37.23% |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 666.6 | 706.3 | 640.3 | 577.3 | 636.2 | 1,251 |
Enterprise Value (EV) 1 | 540.7 | 661.3 | 667.2 | 998.2 | 936.6 | 1,288 |
P/E ratio | 24.6 x | 33.5 x | 88.5 x | -9.07 x | -13.9 x | -19.7 x |
Yield | 3.5% | 2.07% | 0.94% | - | 4.13% | 2.63% |
Capitalization / Revenue | 1.07 x | 1.09 x | 1.06 x | 1.23 x | 1.47 x | 3.25 x |
EV / Revenue | 0.87 x | 1.02 x | 1.1 x | 2.12 x | 2.16 x | 3.35 x |
EV / EBITDA | 12.7 x | 12.3 x | 17.2 x | -25.1 x | -25 x | -129 x |
EV / FCF | -3.73 x | -14.5 x | -11.5 x | -2.69 x | 25.2 x | -4.29 x |
FCF Yield | -26.8% | -6.9% | -8.68% | -37.2% | 3.97% | -23.3% |
Price to Book | 0.94 x | 1.02 x | 0.91 x | 0.86 x | 0.87 x | 1.31 x |
Nbr of stocks (in thousands) | 32,091 | 32,170 | 33,145 | 33,082 | 39,514 | 59,710 |
Reference price 2 | 20.77 | 21.95 | 19.32 | 17.45 | 16.10 | 20.95 |
Announcement Date | 28/03/19 | 31/03/20 | 24/03/21 | 29/03/22 | 29/03/23 | 29/03/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 622.8 | 646.6 | 605.2 | 470.6 | 433.6 | 384.4 |
EBITDA 1 | 42.61 | 53.89 | 38.82 | -39.81 | -37.48 | -9.98 |
EBIT 1 | 31.24 | 39.13 | 15.39 | -63.77 | -62.47 | -29.93 |
Operating Margin | 5.02% | 6.05% | 2.54% | -13.55% | -14.41% | -7.79% |
Earnings before Tax (EBT) 1 | 33.53 | 31.7 | 11.63 | -71.62 | -49.06 | -55.95 |
Net income 1 | 25.14 | 21.19 | 7.193 | -62.45 | -44.66 | -57.02 |
Net margin | 4.04% | 3.28% | 1.19% | -13.27% | -10.3% | -14.83% |
EPS 2 | 0.8455 | 0.6545 | 0.2182 | -1.923 | -1.154 | -1.066 |
Free Cash Flow 1 | -145 | -45.66 | -57.95 | -371.6 | 37.17 | -300.2 |
FCF margin | -23.27% | -7.06% | -9.57% | -78.95% | 8.57% | -78.1% |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share 2 | 0.7273 | 0.4545 | 0.1819 | - | 0.6650 | 0.5500 |
Announcement Date | 28/03/19 | 31/03/20 | 24/03/21 | 29/03/22 | 29/03/23 | 29/03/24 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | 26.9 | 421 | 300 | 37.5 |
Net Cash position 1 | 126 | 45 | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | 0.6937 x | -10.57 x | -8.016 x | -3.761 x |
Free Cash Flow 1 | -145 | -45.7 | -57.9 | -372 | 37.2 | -300 |
ROE (net income / shareholders' equity) | 3.77% | 3.01% | 1.03% | -9.08% | -6.37% | -6.77% |
ROA (Net income/ Total Assets) | 2.31% | 2.78% | 0.97% | -3.33% | -2.98% | -1.39% |
Assets 1 | 1,090 | 763.2 | 739.2 | 1,875 | 1,497 | 4,088 |
Book Value Per Share 2 | 22.10 | 21.60 | 21.10 | 20.40 | 18.40 | 16.00 |
Cash Flow per Share 2 | 6.210 | 6.390 | 8.010 | 5.960 | 4.940 | 6.360 |
Capex 1 | 163 | 91.8 | 17.8 | 332 | 20 | 18.9 |
Capex / Sales | 26.18% | 14.2% | 2.94% | 70.56% | 4.61% | 4.91% |
Announcement Date | 28/03/19 | 31/03/20 | 24/03/21 | 29/03/22 | 29/03/23 | 29/03/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+37.23% | 51.31M | |
-1.08% | 277B | |
-7.03% | 91.92B | |
-5.18% | 42.95B | |
+0.95% | 41.25B | |
+4.86% | 40.01B | |
+4.08% | 38.81B | |
-15.06% | 30.87B | |
-11.47% | 27.21B | |
+8.20% | 24.19B |
- Stock Market
- Equities
- 6578 Stock
- Financials DaBomb Protein Biotech Corp.